Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS
Michael Benatar, Lanyu Zhang, Lily Wang, et al.
Neurology (2020) Vol. 95, Iss. 1
Open Access | Times Cited: 171

Showing 1-25 of 171 citing articles:

Amyotrophic lateral sclerosis
Eva L. Feldman, Stephen A. Goutman, Susanne Petri, et al.
The Lancet (2022) Vol. 400, Iss. 10360, pp. 1363-1380
Open Access | Times Cited: 562
Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS
Jonathan Mill, Merit Cudkowicz, Angela Genge, et al.
New England Journal of Medicine (2022) Vol. 387, Iss. 12, pp. 1099-1110
Open Access | Times Cited: 541
Trial of Sodium Phenylbutyrate–Taurursodiol for Amyotrophic Lateral Sclerosis
Sabrina Paganoni, Eric A. Macklin, Suzanne Hendrix, et al.
New England Journal of Medicine (2020) Vol. 383, Iss. 10, pp. 919-930
Open Access | Times Cited: 443
The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease
Oskar Hansson, Rebecca M. Edelmayer, Adam L. Boxer, et al.
Alzheimer s & Dementia (2022) Vol. 18, Iss. 12, pp. 2669-2686
Open Access | Times Cited: 368
Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis
Stephen A. Goutman, Orla Hardiman, Ammar Al‐Chalabi, et al.
The Lancet Neurology (2022) Vol. 21, Iss. 5, pp. 480-493
Open Access | Times Cited: 288
Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation
Richard J. Mead, Ning Shan, H. Joseph Reiser, et al.
Nature Reviews Drug Discovery (2022) Vol. 22, Iss. 3, pp. 185-212
Open Access | Times Cited: 269
Blood biomarkers for Alzheimer’s disease in clinical practice and trials
Oskar Hansson, Kaj Blennow, Henrik Zetterberg, et al.
Nature Aging (2023) Vol. 3, Iss. 5, pp. 506-519
Open Access | Times Cited: 227
Blood neurofilament light: a critical review of its application to neurologic disease
Christian Barro, Tanuja Chitnis, Howard L. Weiner
Annals of Clinical and Translational Neurology (2020) Vol. 7, Iss. 12, pp. 2508-2523
Open Access | Times Cited: 204
Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p‐tau
Shorena Janelidze, Sebastian Palmqvist, Antoine Leuzy, et al.
Alzheimer s & Dementia (2021) Vol. 18, Iss. 2, pp. 283-293
Open Access | Times Cited: 132
Neurofilaments as biomarkers in neurological disorders — towards clinical application
Michael Khalil, Charlotte E. Teunissen, Sylvain Lehmann, et al.
Nature Reviews Neurology (2024) Vol. 20, Iss. 5, pp. 269-287
Closed Access | Times Cited: 122
Neurofilament Light Chain as Biomarker for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
Federico Verde, Markus Otto, Vincenzo Silani
Frontiers in Neuroscience (2021) Vol. 15
Open Access | Times Cited: 106
A fluid biomarker reveals loss of TDP-43 splicing repression in presymptomatic ALS–FTD
Katherine E. Irwin, Pei Jasin, Kerstin E. Braunstein, et al.
Nature Medicine (2024) Vol. 30, Iss. 2, pp. 382-393
Open Access | Times Cited: 65
Neurofilament light chain response during therapy with antisense oligonucleotide Tofersen in SOD1 ‐related ALS – treatment experience in clinical practice
Thomas Meyer, Peggy Schumann, Patrick Weydt, et al.
Muscle & Nerve (2023) Vol. 67, Iss. 6, pp. 515-521
Open Access | Times Cited: 59
Fluid biomarkers for amyotrophic lateral sclerosis: a review
Katherine E. Irwin, Udit Sheth, Philip C. Wong, et al.
Molecular Neurodegeneration (2024) Vol. 19, Iss. 1
Open Access | Times Cited: 29
Safety, tolerability, and pharmacokinetics of antisense oligonucleotide BIIB078 in adults with C9orf72-associated amyotrophic lateral sclerosis: a phase 1, randomised, double blinded, placebo-controlled, multiple ascending dose study
Leonard H. van den Berg, Jeffrey D. Rothstein, Pamela J. Shaw, et al.
The Lancet Neurology (2024) Vol. 23, Iss. 9, pp. 901-912
Closed Access | Times Cited: 24
Secreted neurofilament light chain after neuronal damage induces myeloid cell activation and neuroinflammation
Olga I. Kahn, Sara L. Domínguez, Caspar Glock, et al.
Cell Reports (2025) Vol. 44, Iss. 3, pp. 115382-115382
Open Access | Times Cited: 2
Circulating miR-181 is a prognostic biomarker for amyotrophic lateral sclerosis
Iddo Magen, Nancy‐Sarah Yacovzada, Eran Yanowski, et al.
Nature Neuroscience (2021) Vol. 24, Iss. 11, pp. 1534-1541
Open Access | Times Cited: 93
Neurofilaments in motor neuron disorders: towards promising diagnostic and prognostic biomarkers
Elisabetta Zucchi, Valentina Bonetto, Gianni Sorarù, et al.
Molecular Neurodegeneration (2020) Vol. 15, Iss. 1
Open Access | Times Cited: 83
Comparison of CSF and serum neurofilament light and heavy chain as differential diagnostic biomarkers for ALS
Steffen Halbgebauer, Petra Steinacker, Federico Verde, et al.
Journal of Neurology Neurosurgery & Psychiatry (2021) Vol. 93, Iss. 1, pp. 68-74
Closed Access | Times Cited: 64
Multicentre appraisal of amyotrophic lateral sclerosis biofluid biomarkers shows primacy of blood neurofilament light chain
Alexander G. Thompson, Elizabeth Gray, Nick Verber, et al.
Brain Communications (2022) Vol. 4, Iss. 1
Open Access | Times Cited: 62
Molecular Biomarkers and Their Implications for the Early Diagnosis of Selected Neurodegenerative Diseases
Julia Doroszkiewicz, Magdalena Groblewska, Barbara Mroczko
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 9, pp. 4610-4610
Open Access | Times Cited: 53
Neurofilament light chain in drug development for amyotrophic lateral sclerosis: a critical appraisal
Michael Benatar, Joanne Wuu, Martin R. Turner
Brain (2022) Vol. 146, Iss. 7, pp. 2711-2716
Open Access | Times Cited: 51
Blood biomarkers in ALS : challenges, applications and novel frontiers
Ellie Sturmey, Andrea Malaspina
Acta Neurologica Scandinavica (2022) Vol. 146, Iss. 4, pp. 375-388
Open Access | Times Cited: 43
Advances in molecular pathology, diagnosis, and treatment of amyotrophic lateral sclerosis
Hristelina Ilieva, Mithila Vullaganti, Justin Kwan
BMJ (2023), pp. e075037-e075037
Open Access | Times Cited: 39
Performance of serum neurofilament light chain in a wide spectrum of clinical courses of amyotrophic lateral sclerosis—a cross‐sectional multicenter study
Thomas Meyer, Erma Salkic, Torsten Grehl, et al.
European Journal of Neurology (2023) Vol. 30, Iss. 6, pp. 1600-1610
Open Access | Times Cited: 29
Page 1 - Next Page

Scroll to top